Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/01/21
End: 08/31/22
Due: 08/31/23
Phase: N/A
Priority: Normal
Start: 05/08/23
End: 09/30/23
Due: 09/30/24
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 10/22/24
End: 11/30/25
Due: 11/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C | NCT05240521 | Devintec Sagl | user2@example.com | None | 2021-11-01 | 2022-08-31 | 2023-08-31 | - | - | 2025-07-14 |
| Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation | NCT05959824 | Devintec Sagl | user2@example.com | None | 2023-05-08 | 2023-09-30 | 2024-09-30 | - | - | 2025-07-14 |
| Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease | NCT06984484 | Devintec Sagl | user2@example.com | None | 2025-05-31 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome | NCT06681012 | Devintec Sagl | user2@example.com | None | 2024-10-22 | 2025-11-30 | 2026-11-30 | - | - | 2025-07-14 |